Horizon Pharma PLC Company Profile (NASDAQ:HZNP)

About Horizon Pharma PLC (NASDAQ:HZNP)

Horizon Pharma PLC logoHorizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:HZNP
  • CUSIP: 44047T10
  • Web: www.horizonpharma.com
Capitalization:
  • Market Cap: $2.09408 billion
  • Outstanding Shares: 162,709,000
Average Prices:
  • 50 Day Moving Avg: $11.86
  • 200 Day Moving Avg: $14.07
  • 52 Week Range: $9.45 - $23.44
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 11.34
  • P/E Growth: 1.19
Sales & Book Value:
  • Annual Revenue: $997.29 million
  • Price / Sales: 2.15
  • Book Value: $7.41 per share
  • Price / Book: 1.78
Profitability:
  • EBIDTA: $244.98 million
  • Net Margins: -21.26%
  • Return on Equity: 21.51%
  • Return on Assets: 7.29%
Debt:
  • Debt-to-Equity Ratio: 1.56%
  • Current Ratio: 1.67%
  • Quick Ratio: 1.48%
Misc:
  • Average Volume: 4.66 million shs.
  • Beta: 1.38
  • Short Ratio: 3.17
 
Frequently Asked Questions for Horizon Pharma PLC (NASDAQ:HZNP)

What is Horizon Pharma PLC's stock symbol?

Horizon Pharma PLC trades on the NASDAQ under the ticker symbol "HZNP."

How will Horizon Pharma PLC's stock buyback program work?

Horizon Pharma PLC announced that its Board of Directors has authorized a share repurchase program on Sunday, June 4th 2017, which permits the company to buyback 1,000% of outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued.

How were Horizon Pharma PLC's earnings last quarter?

Horizon Pharma PLC (NASDAQ:HZNP) announced its quarterly earnings results on Monday, May, 8th. The company reported $0.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.25 by $0.04. The firm earned $220.90 million during the quarter, compared to analysts' expectations of $248.71 million. Horizon Pharma PLC had a positive return on equity of 21.51% and a negative net margin of 21.26%. The company's revenue for the quarter was up 7.9% on a year-over-year basis. During the same period last year, the firm posted $0.34 earnings per share. View Horizon Pharma PLC's Earnings History.

Where is Horizon Pharma PLC's stock going? Where will Horizon Pharma PLC's stock price be in 2017?

12 brokerages have issued 1 year price objectives for Horizon Pharma PLC's shares. Their predictions range from $10.00 to $32.00. On average, they expect Horizon Pharma PLC's stock price to reach $20.42 in the next year. View Analyst Ratings for Horizon Pharma PLC.

What are analysts saying about Horizon Pharma PLC stock?

Here are some recent quotes from research analysts about Horizon Pharma PLC stock:

  • 1. According to Zacks Investment Research, "Horizon’s results from the primary care business units was much below expectations in the first quarter due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. The company plans to overcome this underperformance by reducing certain costs in the primary care business unit in order to align its cost structure with the lower- than-expected sales. Due to the divestiture of Procysbi, the company now expects sales in 2017 to come around $985 million to $1.020 billion. On a positive note, Horizon is significantly increasing investments in one its key drugs, Krystexxa. Shares of the company have underperformed the Zacks classified industry." (7/11/2017)
  • 2. Piper Jaffray Companies analysts commented, "We had the opportunity to travel with Horizon senior management in meetings with investors. We gained additional insight into Pennsaid 2% and Ravicti, and also came away with insights into management's latest thinking regarding M&A. Though there are undoubtedly some headwinds facing the primary care segment, we believe that this segment should be on largely stable footing over the long-term given HZNP's payer contracting efforts. That dynamic combined with continued strength from the rare disease segment points to a long-term EPS CAGR (2017-2022) in the mid-teens, and should translate into multiple expansion with a 2017E P/E currently at 7x. We reiterate our Overweight rating and are lowering our PT to $30 from $32 (see below for more details)." (3/24/2017)
  • 3. Guggenheim analysts commented, "HZNP reported a 4Q16 beat, underscoring our confidence that HZNP can continue to meet or exceed earnings expectations in '17+. Post 4Q16, we think that the peak sales potential of Pennsaid 2%, Procysbi, and Krystexxa are underappreciated, with additional earnings upside potentially coming from M&A as HZNP redeploys cash generated by its Primary Care ("PC") business into business development focused on orphan and rare disease indication medicines. While concerns remain over growth prospects for HZNP's PC business, Ravicti and Actimmune, these assets continue to generate meaningful cash to fuel HZNP's growth aspiration of $2B in sales by 2020." (2/27/2017)
  • 4. Mizuho analysts commented, "We are positive on HZNP ahead of the February 27 earnings call: We think the company may deliver a 4Q:16 earnings beat. We model 4Q:16 revenues of $325.4M and EPS of $0.57 relative to consensus $308.5M and $0.50 and implied guidance $309-$314M. Horizon has delivered strong beats in the past and we expect adjusted EBITDA to approach the higher end of the guidance range of $450-$460M. With respect to 2017 guidance, we fall below FactSet consensus estimates of $1,289.7M and $2.39 (we model $1,281.8M and $2.29), but note that Horizon may be able to beat this range via a combination of both price and volume growth, so guidance could come in stronger than expected. There is still significant uncertainty around business operation under the new PBM contracts, gross to net discounts, infrastructure needs, and the timing of anticipated volume growth. We therefore expect the focus of the call to be around these issues as well as on future business development targets and pipeline outlook." (2/22/2017)

Are investors shorting Horizon Pharma PLC?

Horizon Pharma PLC saw a increase in short interest during the month of June. As of June 15th, there was short interest totalling 14,604,104 shares, an increase of 15.1% from the May 31st total of 12,691,454 shares. Based on an average daily volume of 4,732,157 shares, the days-to-cover ratio is presently 3.1 days. Currently, 9.1% of the company's shares are short sold.

Who are some of Horizon Pharma PLC's key competitors?

Who are Horizon Pharma PLC's key executives?

Horizon Pharma PLC's management team includes the folowing people:

  • Timothy P. Walbert, Chairman of the Board, President, Chief Executive Officer
  • Paul W. Hoelscher, Chief Financial Officer, Executive Vice President
  • Brian K. Beeler, Executive Vice President, General Counsel
  • David G. Kelly, Executive Vice President, Company Secretary and Managing Director, Ireland
  • John B. Thomas, Executive Vice President, Strategy and Investor Relations
  • Robert F. Carey, Executive Vice President, Chief Business Officer
  • George P. Hampton, Executive Vice President - Orphan and Primary Care Business Units and International Operations
  • Jeffrey W. Sherman M.D., Executive Vice President - Research and Development and Chief Medical Officer
  • Timothy J. Ackerman, Senior Vice President - Commercial Operations
  • Geoffrey M. Curtis, Senior Vice President - Corporate Communications

Who owns Horizon Pharma PLC stock?

Horizon Pharma PLC's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Deltec Asset Management LLC (0.15%), American National Insurance Co. TX (0.09%), US Bancorp DE (0.05%), Creative Planning (0.04%), Malaga Cove Capital LLC (0.03%) and Fox Run Management L.L.C. (0.02%). Company insiders that own Horizon Pharma PLC stock include Jeffrey W Sherman, Michael G Grey, Robert Carey and Virinder Nohria. View Institutional Ownership Trends for Horizon Pharma PLC.

Who sold Horizon Pharma PLC stock? Who is selling Horizon Pharma PLC stock?

Horizon Pharma PLC's stock was sold by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have sold Horizon Pharma PLC stock in the last year include Jeffrey W Sherman and Robert Carey. View Insider Buying and Selling for Horizon Pharma PLC.

Who bought Horizon Pharma PLC stock? Who is buying Horizon Pharma PLC stock?

Horizon Pharma PLC's stock was acquired by a variety of institutional investors in the last quarter, including Malaga Cove Capital LLC, US Bancorp DE, Deltec Asset Management LLC, Fox Run Management L.L.C. and Bank of Montreal Can. View Insider Buying and Selling for Horizon Pharma PLC.

How do I buy Horizon Pharma PLC stock?

Shares of Horizon Pharma PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Horizon Pharma PLC's stock price today?

One share of Horizon Pharma PLC stock can currently be purchased for approximately $13.16.


MarketBeat Community Rating for Horizon Pharma PLC (NASDAQ HZNP)
Community Ranking:  3.9 out of 5 (  )
Outperform Votes:  462 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  599
MarketBeat's community ratings are surveys of what our community members think about Horizon Pharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Horizon Pharma PLC (NASDAQ:HZNP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $20.42 (55.14% upside)

Analysts' Ratings History for Horizon Pharma PLC (NASDAQ:HZNP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/14/2017Jefferies Group LLCReiterated RatingBuy$14.00LowView Rating Details
6/16/2017Cantor FitzgeraldInitiated CoverageOverweight -> Overweight$13.00LowView Rating Details
5/9/2017Citigroup Inc.Lower Price TargetBuy$20.00 -> $13.00MediumView Rating Details
5/9/2017Stifel NicolausReiterated RatingBuy -> Buy$35.00 -> $20.00HighView Rating Details
5/9/2017Cowen and CompanySet Price TargetOutperform$42.00 -> $20.00MediumView Rating Details
5/9/2017MizuhoDowngradeBuy -> Neutral$22.00 -> $10.00HighView Rating Details
5/9/2017BMO Capital MarketsReiterated RatingBuy$24.00 -> $17.00HighView Rating Details
3/24/2017Piper Jaffray CompaniesLower Price TargetOverweight$32.00 -> $30.00LowView Rating Details
2/28/2017Morgan StanleyReiterated RatingEqual Weight$20.00N/AView Rating Details
2/27/2017GuggenheimInitiated CoverageBuy$30.00N/AView Rating Details
10/12/2016Goldman Sachs Group, Inc. (The)Set Price TargetBuy$26.00N/AView Rating Details
9/12/2016Brean CapitalReiterated RatingBuy$32.00N/AView Rating Details
11/11/2015WallachBeth CapitalUpgradeBuyN/AView Rating Details
10/22/2015JMP SecuritiesReiterated RatingBuyN/AView Rating Details
(Data available from 7/25/2015 forward)

Earnings

Earnings History for Horizon Pharma PLC (NASDAQ:HZNP)
Earnings by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)
Earnings History by Quarter for Horizon Pharma PLC (NASDAQ HZNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017$0.25$0.21$248.71 million$220.90 millionViewListenView Earnings Details
2/27/2017Q416$0.51$0.64$307.93 million$310.30 millionViewListenView Earnings Details
11/7/2016Q316$0.63$0.70$270.04 million$273.70 millionViewListenView Earnings Details
8/8/2016Q216$0.50$0.62$235.43 million$257.40 millionViewN/AView Earnings Details
5/9/2016Q116$0.30$0.34$197.73 million$204.70 millionViewN/AView Earnings Details
2/29/2016Q415$0.62$0.63$240.92 million$244.50 millionViewListenView Earnings Details
11/6/2015Q315$0.41$0.59$185.70 million$292.70 millionViewListenView Earnings Details
8/7/2015Q215$0.32$0.39$156.41 million$172.80 millionViewListenView Earnings Details
5/8/2015Q115$0.22$0.16$104.20 million$113.10 millionViewN/AView Earnings Details
2/27/2015Q414$0.23$0.27$95.50 million$103.80 millionViewN/AView Earnings Details
11/6/2014Q314$0.19$0.24$73.17 million$75.10 millionViewN/AView Earnings Details
8/7/2014Q214$0.16$0.14$58.35 million$66.10 millionViewN/AView Earnings Details
5/9/2014Q114$0.01$0.10$42.69 million$51.90 millionViewN/AView Earnings Details
3/13/2014Q413($0.08)($0.22)$32.20 million$43.10 millionViewN/AView Earnings Details
11/8/2013Q3 13($0.25)($0.03)$18.31 million$31.50 millionViewN/AView Earnings Details
8/9/2013Q213($0.32)($0.24)$16.09 million$17.64 millionViewN/AView Earnings Details
5/10/2013Q113($0.35)($0.30)$9.47 million$9.20 millionViewN/AView Earnings Details
11/13/2012Q312($0.68)($0.39)$4.12 million$7.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Horizon Pharma PLC (NASDAQ:HZNP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171$0.10$0.10$0.10
Q3 20171$0.25$0.25$0.25
Q4 20171$0.29$0.29$0.29
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Horizon Pharma PLC (NASDAQ:HZNP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Horizon Pharma PLC (NASDAQ:HZNP)
Insider Ownership Percentage: 3.20%
Institutional Ownership Percentage: 84.09%
Insider Trades by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)
Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)
Insider Trades by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/10/2017Michael G GreyDirectorBuy10,000$9.48$94,800.00View SEC Filing  
3/1/2017Robert CareyEVPSell31,808$16.03$509,882.24View SEC Filing  
8/2/2016Jeffrey W. ShermanEVPSell2,900$20.00$58,000.00View SEC Filing  
6/15/2016Virinder NohriaDirectorSell25,000$17.69$442,250.00View SEC Filing  
2/26/2016Jeffrey W ShermanEVPSell4,100$20.00$82,000.00View SEC Filing  
12/10/2015Jeffrey W ShermanEVPSell4,456$20.00$89,120.00View SEC Filing  
9/21/2015Jeffrey W ShermanEVPSell7,750$31.78$246,295.00View SEC Filing  
7/15/2015Jeffrey W ShermanEVPSell26,887$35.55$955,832.85View SEC Filing  
3/13/2015Jeff HimawanDirectorSell554,564$22.44$12,444,416.16View SEC Filing  
3/10/2015Jeff HimawanDirectorSell1,614,827$21.85$35,283,969.95View SEC Filing  
11/19/2014Jeff HimawanDirectorSell3,450,000$12.05$41,572,500.00View SEC Filing  
11/19/2014Jeffrey W ShermanEVPSell24,999$12.05$301,237.95View SEC Filing  
11/19/2014Timothy P WalbertCEOSell150,000$12.05$1,807,500.00View SEC Filing  
11/13/2014Balaji VenkataramanMajor ShareholderSell6,086,957$11.54$70,243,483.78View SEC Filing  
11/13/2014Virinder NohriaDirectorSell1,739,130$11.54$20,069,560.20View SEC Filing  
9/30/2014Vaere Robert J DeCFOSell51,942$12.28$637,847.76View SEC Filing  
5/19/2014Timothy WalbertCEOSell31,742$12.94$410,741.48View SEC Filing  
5/19/2014Todd SmithEVPSell10,159$12.94$131,457.46View SEC Filing  
5/19/2014Vaere Robert DeCFOSell12,939$12.94$167,430.66View SEC Filing  
12/13/2013Jeffrey BirdDirectorBuy668,673$6.50$4,346,374.50View SEC Filing  
12/9/2013Timothy WalbertCEOSell12,124$6.79$82,321.96View SEC Filing  
12/9/2013Todd SmithEVPSell11,322$6.91$78,235.02View SEC Filing  
11/21/2013Jeffrey BirdDirectorBuy151,089$6.24$942,795.36View SEC Filing  
9/25/2012Jeffrey W BirdDirectorBuy575,356$3.49$2,007,992.44View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Horizon Pharma PLC (NASDAQ:HZNP)
Latest Headlines for Horizon Pharma PLC (NASDAQ:HZNP)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Horizon Pharma Plc : July 24, 2017
finance.yahoo.com - July 24 at 11:18 PM
streetinsider.com logoUPDATE: Horizon Pharma (HZNP) Presents Study Results for ... - StreetInsider.com
www.streetinsider.com - July 16 at 11:45 AM
americanbankingnews.com logoHorizon Pharma PLC's (HZNP) "Buy" Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - July 15 at 4:12 PM
streetinsider.com logoUPDATE: Horizon Pharma (HZNP) Presents Study Results for PROCYSBI (Cysteamine Bitartrate) Delayed-Release Capsules
www.streetinsider.com - July 15 at 1:12 AM
finance.yahoo.com logoHorizon Pharma plc Announces Four Poster Presentations on PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Capsules at Cystinosis Research Network 2017 Family Conference
finance.yahoo.com - July 15 at 1:12 AM
finance.yahoo.com logoETFs with exposure to Horizon Pharma Plc : July 14, 2017
finance.yahoo.com - July 15 at 1:12 AM
nasdaq.com logoCommit To Buy Horizon Pharma At $8, Earn 11.2% Using Options - Nasdaq
www.nasdaq.com - July 11 at 11:25 PM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - July 11 at 4:52 PM
nasdaq.com logoHorizon Pharma plc to Host Second-Quarter 2017 Conference Call and Webcast on ...
www.nasdaq.com - July 10 at 7:39 PM
feeds.benzinga.com logoHorizon Pharma plc to Host Second-Quarter 2017 Conference Call and Webcast on Aug. 7, 2017
feeds.benzinga.com - July 10 at 11:44 AM
americanbankingnews.com logoHorizon Pharma PLC (NASDAQ:HZNP) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 3 at 12:40 PM
americanbankingnews.com logoResearch Analysts Issue Forecasts for Horizon Pharma PLC's FY2018 Earnings (NASDAQ:HZNP)
www.americanbankingnews.com - July 3 at 9:41 AM
finance.yahoo.com logoHorizon Pharma Plc – Value Analysis (NASDAQ:HZNP) : June 28, 2017
finance.yahoo.com - June 28 at 7:15 PM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) & Aquinox Pharmaceuticals (AQXP) Head-To-Head Review
www.americanbankingnews.com - June 28 at 7:56 AM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Short Interest Update
www.americanbankingnews.com - June 28 at 7:12 AM
streetinsider.com logoUPDATE: Horizon Pharma (HZNP) Says District Court Upheld VIMOVO Patents - StreetInsider.com
www.streetinsider.com - June 28 at 4:02 AM
finance.yahoo.com logoHorizon Pharma plc Announces District Court Decision to Uphold VIMOVO® (naproxen/esomeprazole magnesium) Patents
finance.yahoo.com - June 27 at 5:59 PM
finance.yahoo.com logoHorizon Pharma Plc breached its 50 day moving average in a Bullish Manner : HZNP-US : June 27, 2017
finance.yahoo.com - June 27 at 5:59 PM
americanbankingnews.com logo Brokerages Expect Horizon Pharma PLC (HZNP) to Post $0.12 Earnings Per Share
www.americanbankingnews.com - June 27 at 7:22 AM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - June 24 at 6:10 PM
finance.yahoo.com logoHorizon Pharma plc Completes Sale of European Marketing Rights for PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin nebuliser solution) in Europe, Middle East and Africa (EMEA) Regions to Chiesi Farmaceutici S.p.A.
finance.yahoo.com - June 23 at 6:06 PM
seekingalpha.com logoHorizon Pharma (HZNP) Presents At JMP Securities Life Sciences Conference - Slideshow
seekingalpha.com - June 22 at 11:23 PM
nasdaq.com logoHorizon Pharma plc Partners with Global Genes® to Unite the Rare Disease ...
www.nasdaq.com - June 20 at 6:37 PM
finance.yahoo.com logoHorizon Pharma Gets Health Canada Approval for Procysbi
finance.yahoo.com - June 20 at 6:37 PM
streetinsider.com logoHorizon Pharma (HZNP) Announces Health Canada Approval of PROCYSBI for Treatment of Nephropathic Cystinosis
www.streetinsider.com - June 19 at 4:45 PM
globenewswire.com logoHorizon Pharma plc Announces Health Canada Approval of PROCYSBI™ (Cysteamine ...
globenewswire.com - June 19 at 12:30 PM
finance.yahoo.com logoHorizon Pharma plc Announces Health Canada Approval of PROCYSBI™ (Cysteamine Delayed-Release Capsules) for the Treatment of Nephropathic Cystinosis
finance.yahoo.com - June 19 at 12:30 PM
finance.yahoo.com logoValeant: Stop Looking in the Rearview Mirror!
finance.yahoo.com - June 16 at 6:38 PM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Coverage Initiated by Analysts at Cantor Fitzgerald
www.americanbankingnews.com - June 16 at 8:48 AM
streetinsider.com logoHorizon Pharma (HZNP) Presents Data Analyses Showing Clinical Benefit of KRYSTEXXA in Patients with Uncontrolled Gout
www.streetinsider.com - June 15 at 12:45 AM
streetinsider.com logoHorizon Pharma (HZNP) Presents Data Analyses Showing Clinical Benefit of KRYSTEXXA in Patients with ... - StreetInsider.com
www.streetinsider.com - June 14 at 11:34 AM
finance.yahoo.com logoEpidemiologic Study Findings Show Over 400 Percent Increase in Gout Patient Hospitalizations Since 1993
finance.yahoo.com - June 14 at 11:33 AM
finance.yahoo.com logoHorizon Pharma plc Presents New Data Analyses Further Demonstrating Clinical Benefit of KRYSTEXXA® (pegloticase) in Patients with Uncontrolled Gout
finance.yahoo.com - June 14 at 11:33 AM
nasdaq.com logoHorizon Pharma (HZNP) Up 11.3% Since Earnings Report: Can It Continue? - Nasdaq
www.nasdaq.com - June 12 at 6:26 PM
finance.yahoo.com logoHorizon Pharma (HZNP) Up 11.3% Since Earnings Report: Can It Continue?
finance.yahoo.com - June 12 at 6:26 PM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 6 at 12:52 PM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Lowered to "Hold" at ValuEngine
www.americanbankingnews.com - June 4 at 11:51 AM
americanbankingnews.com logoStock Repurchase Plan Declared by Horizon Pharma PLC (HZNP) Board
www.americanbankingnews.com - June 4 at 11:28 AM
americanbankingnews.com logoZacks: Analysts Expect Horizon Pharma PLC (HZNP) Will Post Quarterly Sales of $235.01 Million
www.americanbankingnews.com - June 3 at 10:30 AM
americanbankingnews.com logo Brokerages Expect Horizon Pharma PLC (HZNP) Will Announce Earnings of $0.12 Per Share
www.americanbankingnews.com - June 1 at 8:32 AM
finance.yahoo.com logoFalling Earnings Estimates Signal Weakness Ahead for Horizon Pharma (HZNP)
finance.yahoo.com - May 31 at 5:43 PM
nasdaq.com logoHorizon Pharma Enters Oversold Territory (HZNP)
www.nasdaq.com - May 30 at 5:39 PM
bizjournals.com logoTechnical Reports on Generic Drugs Stocks -- Mylan, Allergan, Horizon Pharma, and Neurocrine Biosciences
www.bizjournals.com - May 30 at 10:41 AM
americanbankingnews.com logoShort Interest in Horizon Pharma PLC (HZNP) Drops By 11.2%
www.americanbankingnews.com - May 27 at 7:16 AM
finance.yahoo.com logoETFs with exposure to Horizon Pharma Plc : May 26, 2017
finance.yahoo.com - May 26 at 6:29 PM
feeds.benzinga.com logoHorizon Pharma plc to Participate in Upcoming Conferences
feeds.benzinga.com - May 26 at 8:21 AM
finance.yahoo.com logoHorizon Pharma plc Named One of the Best Workplaces in Chicago by Fortune
finance.yahoo.com - May 25 at 8:57 PM
streetinsider.com logoHorizon Pharma (HZNP) to Sell European Marketing Rights to PROCYSBI and EMEA Rights to QUINSAIR
www.streetinsider.com - May 24 at 10:42 PM
seekingalpha.com logoHorizon Pharma sells certain ex-U.S. rights to Procysbi and Quinsair for $70M - Seeking Alpha
seekingalpha.com - May 24 at 11:40 AM
streetinsider.com logoHorizon Pharma (HZNP) to Sell European Marketing Rights to PROCYSBI and EMEA Rights to QUINSAIR - StreetInsider.com
www.streetinsider.com - May 24 at 11:40 AM

Social

Chart

Horizon Pharma PLC (HZNP) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by MarketBeat.com Staff